Prosecution Insights
Last updated: May 29, 2026

Health Research Inc.

8 pending office actions • 8 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days

Portfolio Summary

8
Total Pending OAs
5
Non-Final OAs
3
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 8 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

5
Overdue
0
Due this week
1
Due this month
1
Due in next 60 days
1
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 8 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (5)Due ≤ 30 days (1)Due ≤ 60 days (1)Due later (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
7
Medium (88%)
1
Easy (12%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only5 (62%)
§102 only2 (25%)
§112 only1 (12%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

5
Life Sciences
62% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
1
Semiconductors
12% of docket
2
Mechanical / Eng
25% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

80 h
Manual time on pending OAs
16 h
Time saved (low, 20%)
28 h
Time saved (mid, 35%)
0.7 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
RZECZYCKI, PHILLIP MATTHEW 1 57.4% +45.0%
HEASLEY, MEGHAN CHRISTINE 1 76.5% +35.6%
TOOHEY, RICHARD ORLANDO 1 82.8% +10.1%
JOHANNSEN, DIANA B 1 53.2% +41.1%
RESTAINO, ANDREW PETER 1 73.3% +41.3%
FONSECA LOPEZ, FRANCINI ALVARENGA 1 25.0% +66.7%
KOLKER, DANIEL E 1 49.8% +64.1%
MOON, MATTHEW RYAN 1 58.5% +61.4%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18040670 METHODS AND SYSTEMS FOR OPTIMIZING VOLUMETRIC MODULATED ARC THERAPY (VMAT) TREATMENT PLANS TOOHEY, RICHARD ORLANDO 16d overdue

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
17523079 ANTI-MICROBIAL PEPTIDES AND METHOD FOR DESIGNING NOVEL ANTI-MICROBIAL PEPTIDES FONSECA LOPEZ, FRANCINI ALVARENGA 34d

Interview Candidates (8)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
17289519 COMBINATION TREATMENT WITH ANTI-CD123 ANTIBODY DRUG CONJUGATE AND PARP INHIBITOR KOLKER, DANIEL E 78d overdue
18253384 COMPOUNDS AND METHODS TO TARGET GLUCOSE-STIMULATED PHOSPHOHISTIDINE SIGNALING AND ESOPHAGEAL CANCER GROWTH RZECZYCKI, PHILLIP MATTHEW 60d overdue
18252024 METHODS FOR DISRUPTING MITOCHONDRIAL UNFOLDED PROTEIN RESPONSE HEASLEY, MEGHAN CHRISTINE 35d overdue
18040670 METHODS AND SYSTEMS FOR OPTIMIZING VOLUMETRIC MODULATED ARC THERAPY (VMAT) TREATMENT PLANS TOOHEY, RICHARD ORLANDO 16d overdue
18001001 JOINTED DEVICE FOR AUTOMATIC SUTURE AND METHOD FOR SAME RESTAINO, ANDREW PETER 5d overdue
16979464 INDUCTION SPACER FOR INHALER MOON, MATTHEW RYAN 14d
17523079 ANTI-MICROBIAL PEPTIDES AND METHOD FOR DESIGNING NOVEL ANTI-MICROBIAL PEPTIDES FONSECA LOPEZ, FRANCINI ALVARENGA 34d
18093066 METHODS RELATED TO BRONCHIAL PREMALIGNANT LESION SEVERITY AND PROGRESSION JOHANNSEN, DIANA B 75d

Top Art Units

Art UnitApps
1625 1
1626 1
2884 1
1682 1
3771 1
1685 1
1645 1
3785 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18253384 COMPOUNDS AND METHODS TO TARGET GLUCOSE-STIMULATED PHOSPHOHISTIDINE SIGNALING AND ESOPHAGEAL CANCER GROWTH RZECZYCKI, PHILLIP MATTHEW 1625 §102 Non-Final OA 60d overdue Pending May 17, 2023
18252024 METHODS FOR DISRUPTING MITOCHONDRIAL UNFOLDED PROTEIN RESPONSE HEASLEY, MEGHAN CHRISTINE 1626 §112 Non-Final OA 35d overdue Pending May 05, 2023
18040670 METHODS AND SYSTEMS FOR OPTIMIZING VOLUMETRIC MODULATED ARC THERAPY (VMAT) TREATMENT PLANS TOOHEY, RICHARD ORLANDO 2884 §102 Non-Final OA 16d overdue Pending Feb 06, 2023
18093066 METHODS RELATED TO BRONCHIAL PREMALIGNANT LESION SEVERITY AND PROGRESSION JOHANNSEN, DIANA B 1682 §103 Final Rejection 75d Pending Jan 04, 2023
18001001 JOINTED DEVICE FOR AUTOMATIC SUTURE AND METHOD FOR SAME RESTAINO, ANDREW PETER 3771 §103 Final Rejection 5d overdue Pending Dec 07, 2022
17523079 ANTI-MICROBIAL PEPTIDES AND METHOD FOR DESIGNING NOVEL ANTI-MICROBIAL PEPTIDES FONSECA LOPEZ, FRANCINI ALVARENGA 1685 §103 Non-Final OA 34d Pending Nov 10, 2021
17289519 COMBINATION TREATMENT WITH ANTI-CD123 ANTIBODY DRUG CONJUGATE AND PARP INHIBITOR KOLKER, DANIEL E 1645 §103 Non-Final OA 78d overdue Pending Apr 28, 2021
16979464 INDUCTION SPACER FOR INHALER MOON, MATTHEW RYAN 3785 §103 Final Rejection 14d Pending Sep 09, 2020

Managing Health Research Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month